Business Context and Reporting Period
This Form 8-K filing by Avalo Therapeutics, Inc. (AVTX) reports a corporate governance event dated October 15, 2021. The Company is a Delaware corporation with its principal executive offices in Rockville, Maryland, and its common stock trades on the Nasdaq Capital Market.
Key Financial Metrics
This filing does not contain current period revenue, profit, cash flow, or margin data. However, it references historical capital raising activities involving Armistice Capital Master Fund Ltd. (Armistice), a significant stockholder:
- September 2021: Underwritten public offering net proceeds of approximately $29.3 million (Armistice purchased 5,454,545 shares).
- January 2021: Underwritten public offering net proceeds of approximately $37.7 million (Armistice purchased 2,500,000 shares).
- June 2020: Underwritten public offering net proceeds of approximately $35.4 million (Armistice purchased 2,000,000 shares).
- March 2020: Securities purchase agreement net proceeds of approximately $3.9 million (Armistice purchased 1,951,219 shares).
- February 2020: Registered direct offering net proceeds of approximately $5.1 million (Armistice purchased 1,256,282 shares).
Debt, liquidity, and operating margin figures are not provided in this document.
Material Changes
The primary material change reported is the appointment of Keith Maher, MD, to the Board of Directors, effective October 15, 2021. Dr. Maher was appointed pursuant to the rights of Armistice Capital Master Fund Ltd. to appoint two directors. He will serve until the 2022 Annual Meeting of Stockholders or until a successor is elected.
Guidance, Outlook, and Risks
This filing contains no forward-looking guidance, financial outlook, or management commentary regarding future operations. The document notes that Dr. Maher is employed by Armistice, which is a significant stockholder, and details the history of transactions between the Company and Armistice to disclose potential related-party dynamics.
Investor Verification Checklist
- Verify the total number of directors currently serving on the Board following Dr. Maher's appointment.
- Confirm the total equity ownership percentage held by Armistice Capital Master Fund Ltd. as of the filing date.
- Review the Company's most recent 10-Q or 10-K for current cash position and burn rate, as this 8-K does not provide liquidity metrics.
- Check for any subsequent filings regarding the 2022 Annual Meeting of Stockholders to confirm Dr. Maher's re-election status.